Pherin Pharmaceuticals Reports Favorable Phase 3 Feasibility Clinical Study on Novel Intranasal Medication for Acute Treatment of Social Anxiety Disorder and Issuance of Patents in the U.S.A. and Other Major Countries
Pherin Article Published in the American Journal of Psychiatry Effect of an Acute Intranasal Aerosol Dose of PH94B on Social and Performance Anxiety in Women With Social Anxiety Disorder.
Pherin Pharmaceuticals at the annual meeting (2015) of the American Society of Clinical Psychopharmacology: PH94B demonstrated effect as PRN treatment for Social Anxiety Disorder in men and women; a phase 3 pilot study.
Pherin Completes Phase 2A Clinical Trials with it’s Acute Antidepressant Product PH10-Nasal Spray A Phase II study in patients diagnosed with Major Depressive disorder showed rapid antidepressant effect.
Pherin Pharmaceuticals, Inc. is the leader in the development of novel compounds for intranasal spray delivery in ultra low (nanogram) dose, without the need of systemic exposure and with demonstrated excellent safety profile.
Currently we have five development programs focused in the acute treatment of neuro-psychiatric and neuroendocrine conditions.
Building a Commercial Infrastructure
We have a diverse product portfolio that increases the probability for commercial success. We believe that the therapeutic advantages of our products will result in pherines becoming an important new class of approved pharmaceuticals.
Unique Nanodose Pharmaceuticals
Pherin Pharmaceuticals, Inc. is a clinical stage specialty drug development company that has developed a first-in-class family of leading and innovative proprietary compounds called pherines for the acute and PRN treatment of neuropsychiatric and neuroendocrine conditions.
Pherin Pharmaceuticals lead program Aloradine NS (PH94B nasal spray) is being developed for the acute treatment of Social Anxiety Disorder under USFDA regulatory guidance.
Evaluation of a new low dose intranasal aerosol in the treatment of clinically significant premenstrual syndrome (2007)
Rapid onset of efficacy and PRN administration for treatment of Social Anxiety Disorder: a multicenter randomized controlled with placebo clinical trial with Aloradine™ nasal spray. Clinically Significant Improvement of Social Anxiety Disorder Symptoms During a Public Speaking Challenge.